-
Mashup Score: 0
Nearly three-quarters of patients with systemic sclerosis demonstrate symptom burden that met the threshold for needing specialist palliative care, according to data published in Arthritis Care & Research. “We are fortunate in our center to have a palliative care unit who are very interested in the implementation of supportive care management for patients with chronic, non-malignant
Source: www.healio.comCategories: General Medicine News, RheumatologyTweet
-
Mashup Score: 1
The FDA has granted orphan drug designation to Cabaletta Bio’s CAR T-cell investigational therapy for the treatment of systemic sclerosis, according to a press release from the manufacturer. The drug, currently known as CABA-201, is a 4-1BB-containing, fully human CD19-CAR T cell, Cabaletta said in the release. According to the company, a clinical trial program including four phase 1/2
Source: www.healio.comCategories: General Medicine News, RheumatologyTweet
-
Mashup Score: 3
DAVIX is a promising surrogate outcome measure of digital ulcer disease in patients with systemic sclerosis. The ability of DAVIX to non-invasively predict future digital ulcers and worsening of patient-reported outcomes could aid patient enrichment and stratification in clinical trials. Clinically, DAVIX could offer insights into the assessment of vascular activity. The sensitivity of DAVIX to change over time and with treatment will establish its value as an imaging outcome measure of vascular disease.
Source: www.thelancet.comCategories: General Medicine News, RheumatologyTweet
-
Mashup Score: 1Hispanic patients with systemic sclerosis have higher mortality rate, risk for lupus - 2 month(s) ago
Hispanic patients with systemic sclerosis are more likely to have concurrent systemic lupus erythematosus and U1-RNP positivity, and face greater mortality rates vs. non-Hispanic white patients, according to data. “Reports suggest ethnical disparities among SSc patients, with potential influence on disease outcomes and survival rates,” Bochra Jandali, MD, of the McGovern Medical
Source: www.healio.comCategories: General Medicine News, RheumatologyTweet
-
Mashup Score: 28
No new safety signals were observed with long-term riociguat in patients with early diffuse cutaneous systemic sclerosis. Study limitations include the absence of a comparator group in this open-label extension study.
Source: www.thelancet.comCategories: General Medicine News, RheumatologyTweet
-
Mashup Score: 1
DAVIX is a promising surrogate outcome measure of digital ulcer disease in patients with systemic sclerosis. The ability of DAVIX to non-invasively predict future digital ulcers and worsening of patient-reported outcomes could aid patient enrichment and stratification in clinical trials. Clinically, DAVIX could offer insights into the assessment of vascular activity. The sensitivity of DAVIX to change over time and with treatment will establish its value as an imaging outcome measure of vascular disease.
Source: www.thelancet.comCategories: Latest Headlines, RheumatologyTweet
-
Mashup Score: 3Beyond very early systemic sclerosis: deciphering pre‑scleroderma and its trajectories to open new avenues for preventive medicine - 7 month(s) ago
The identification of individuals with systemic sclerosis in an oligosymptomatic phase preceding the very early manifestations of the disease represents a challenge in the search for a new window of opportunity in systemic sclerosis. This phase could be identified in a clinical scenario as the pre-scleroderma phase, in which the disease would still be far from systemic sclerosis-related fibrotic or irreversible manifestations in skin or organs. In this Personal View, we discuss parameters and candidate definitions for a conceptual framework of pre-scleroderma, from the identification of populations at risk to autoantibodies and their potential functional activities.
Source: www.thelancet.comCategories: Latest Headlines, RheumatologyTweet
-
Mashup Score: 1
DAVIX is a promising surrogate outcome measure of digital ulcer disease in patients with systemic sclerosis. The ability of DAVIX to non-invasively predict future digital ulcers and worsening of patient-reported outcomes could aid patient enrichment and stratification in clinical trials. Clinically, DAVIX could offer insights into the assessment of vascular activity. The sensitivity of DAVIX to change over time and with treatment will establish its value as an imaging outcome measure of vascular disease.
Source: www.thelancet.comCategories: Latest Headlines, RheumatologyTweet
-
Mashup Score: 0EULAR recommendations for the non-pharmacological management of systemic lupus erythematosus and systemic sclerosis - 9 month(s) ago
Objective To develop evidence-based recommendations for the non-pharmacological management of systemic lupus erythematosus (SLE) and systemic sclerosis (SSc). Methods A task force comprising 7 rheumatologists, 15 other healthcare professionals and 3 patients was established. Following a systematic literature review performed to inform the recommendations, statements were formulated, discussed…
Source: Annals of the Rheumatic DiseasesCategories: Latest Headlines, RheumatologyTweet-
Non-pharmacological management of #lupus & #SystemicSclerosis should ➡️Tailor to patients’ needs, expectations, preferences ➡️Based on shared-decision making ➡️Not substitute for pharmaceutical treatment when required 👉🏽https://t.co/Xt23WRMegi by @IoannisParodis et al @ARD_BMJ https://t.co/ZPcdkP5ycK
-
-
Mashup Score: 0A Phenome-Wide Association Study of Drugs and Comorbidities Associated With Gastrointestinal Dysfunction in Systemic Sclerosis - 9 month(s) ago
Objective To explore the causes of and contributors to gastrointestinal (GI) dysfunction in systemic sclerosis (SSc) in a phenome-wide association study (PheWAS), using real-world clinical records data. Methods Twelve thousand five hundred thirty-five documented clinical assessments of 2058 consenting individuals with SSc at the Royal Free Hospital (UK) were available for detailed phenotyping….
Source: The Journal of RheumatologyCategories: Latest Headlines, RheumatologyTweet
👩⚕️ Nearly 75% of patients with #SystemicSclerosis met criteria for needing specialist palliative care in a study out of @UniMelb Check Healio for more info 👇 https://t.co/AWt8mMh444